US 12,005,120 B2
Galnac conjugated modified oligonucleotides as miR-122 inhibitor having HCV antiviral activity with reduced hyperbilirubinemia side-effect
Charles R. Allerson, San Diego, CA (US); Steven S. Neben, Del Mar, CA (US); and Timothy Wright, San Diego, CA (US)
Assigned to Regulus Therapeutics Inc., San Diego, CA (US)
Appl. No. 17/052,333
Filed by Regulus Therapeutics Inc., San Diego, CA (US)
PCT Filed May 7, 2019, PCT No. PCT/US2019/031044
§ 371(c)(1), (2) Date Nov. 2, 2020,
PCT Pub. No. WO2019/217369, PCT Pub. Date Nov. 14, 2019.
Claims priority of provisional application 62/668,467, filed on May 8, 2018.
Prior Publication US 2021/0170034 A1, Jun. 10, 2021
Int. Cl. A61K 47/54 (2017.01); A61K 31/439 (2006.01); A61K 31/7072 (2006.01); A61K 31/7088 (2006.01); A61P 31/14 (2006.01)
CPC A61K 47/549 (2017.08) [A61K 31/439 (2013.01); A61K 31/7072 (2013.01); A61K 31/7088 (2013.01); A61P 31/14 (2018.01)] 22 Claims
 
1. A compound of the structure:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.